Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.60
- Piotroski Score 2.00
- Grade Buy
- Symbol (APM)
- Company Aptorum Group Limited
- Price $0.73
- Changes Percentage (-0.38%)
- Change -$0
- Day Low $0.69
- Day High $0.74
- Year High $17.49
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/20/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.62
- Trailing P/E Ratio -7.1
- Forward P/E Ratio -7.1
- P/E Growth -7.1
- Net Income $-2,824,647
Income Statement
Quarterly
Annual
Latest News of APM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Luke Combs Calls 'Fast Car' Grammy Duet with Tracy Chapman a 'Total Pinch Me' Experience: 'Amazing'
Luke Combs had a career-defining moment with his hit cover of Tracy Chapman's "Fast Car," reaching the top of the charts and performing with Chapman at the Grammys. The song became a significant part ...
By PEOPLE.com | 1 week ago -
Luke Combs 'Wanted to Crawl Into a Hole' After Tracy Chapman Pointed Out His 'Fast Car' Cover Mistake
Country musician Luke Combs, known for his Grammy-nominated cover of Tracy Chapman's "Fast Car," revealed an embarrassing mistake in his rendition during a recent concert. Chapman graciously corrected...
By PEOPLE.com | 2 weeks ago -
Giants' Matt Chapman wins 5th Gold Glove, Patrick Bailey among first-time winners
San Francisco's Matt Chapman won his fifth Gold Glove, while Patrick Bailey was among 14 first-time winners. Chapman's first NL Gold Glove adds to his three with Oakland and one with Toronto....
By CBS News | 2 weeks ago
